Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial
暂无分享,去创建一个
[1] K. Miskowiak,et al. Structural changes in the hippocampus as a biomarker for cognitive improvements in neuropsychiatric disorders: A systematic review , 2019, European Neuropsychopharmacology.
[2] Marcelo Antônio Oliveira Santos,et al. Global hippocampal atrophy in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. , 2018, Trends in psychiatry and psychotherapy.
[3] K. Miskowiak,et al. Neural and Behavioral Predictors of Treatment Efficacy on Mood Symptoms and Cognition in Mood Disorders: A Systematic Review , 2018, Front. Psychiatry.
[4] Ling Yue,et al. Asymmetry of Hippocampus and Amygdala Defect in Subjective Cognitive Decline Among the Community Dwelling Chinese , 2018, Front. Psychiatry.
[5] Bruce Fischl,et al. False positive rates in surface-based anatomical analysis , 2018, NeuroImage.
[6] R. Bucks,et al. Hippocampal atrophy, asymmetry, and cognition in type 2 diabetes mellitus , 2017, Brain and behavior.
[7] E. Vieta,et al. Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives. , 2017, Journal of affective disorders.
[8] A. Young,et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force , 2017, Bipolar disorders.
[9] A. Meyer-Lindenberg,et al. Hippocampal–prefrontal connectivity as a translational phenotype for schizophrenia , 2017, European Neuropsychopharmacology.
[10] M. Vinberg,et al. Targeting Treatments to Improve Cognitive Function in Mood Disorder: Suggestions From Trials Using Erythropoietin. , 2016, Journal of Clinical Psychiatry.
[11] K. Miskowiak,et al. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field , 2016, European Neuropsychopharmacology.
[12] Jonathan J. Evans,et al. Prevalence and correlates of cognitive impairment in euthymic adults with bipolar disorder: A systematic review. , 2016, Journal of affective disorders.
[13] M. Vinberg,et al. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: Associations with functional abilities. , 2016, Journal of affective disorders.
[14] M. Vinberg,et al. The effect of erythropoietin on cognition in affective disorders – Associations with baseline deficits and change in subjective cognitive complaints , 2016, European Neuropsychopharmacology.
[15] H. Ullum,et al. Screening for cognitive dysfunction in unipolar depression: Validation and evaluation of objective and subjective tools. , 2016, Journal of affective disorders.
[16] H. Siebner,et al. Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders , 2015, Biological Psychiatry.
[17] M. Leboyer,et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report , 2014, Acta psychiatrica Scandinavica.
[18] P. Andersen,et al. Starting lithium prophylaxis early v. late in bipolar disorder , 2014, British Journal of Psychiatry.
[19] Joaquim Radua,et al. Structural Abnormalities in Bipolar Euthymia: A Multicontrast Molecular Diffusion Imaging Study , 2014, Biological Psychiatry.
[20] M. Vinberg,et al. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial. , 2014, The Journal of clinical psychiatry.
[21] J. Bukh,et al. Recombinant Human Erythropoietin for Treating Treatment-Resistant Depression: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial , 2014, Neuropsychopharmacology.
[22] T. Vos,et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet.
[23] R. Lebel,et al. Structural Changes in Hippocampal Subfields in Major Depressive Disorder: A High-Field Magnetic Resonance Imaging Study , 2013, Biological Psychiatry.
[24] R M Peshock,et al. MR Imaging of Hippocampal Asymmetry at 3T in a Multiethnic, Population-Based Sample: Results from the Dallas Heart Study , 2013, American Journal of Neuroradiology.
[25] Torbjørn Elvsåshagen,et al. Evidence for reduced dentate gyrus and fimbria volume in bipolar II disorder , 2013, Bipolar disorders.
[26] G. MacQueen,et al. The Hippocampus in Major Depression , 2012 .
[27] M. Keshavan,et al. A broad cortical reserve accelerates response to cognitive enhancement therapy in early course schizophrenia , 2011, Schizophrenia Research.
[28] Sébastien Ourselin,et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance? , 2010, NeuroImage.
[29] Nicholas D. Walsh,et al. Subregional hippocampal deformations in major depressive disorder. , 2010, Journal of affective disorders.
[30] Nicolas Cherbuin,et al. Mild Cognitive Disorders are Associated with Different Patterns of Brain asymmetry than Normal Aging: The PATH through Life Study , 2010, Front. Psychiatry.
[31] G. Wörtwein,et al. Electroconvulsive stimulations prevent stress-induced morphological changes in the hippocampus , 2008, Stress.
[32] M. Joëls,et al. Opposite effects of glucocorticoid receptor activation on hippocampal CA1 dendritic complexity in chronically stressed and handled animals , 2008, Hippocampus.
[33] B. Czéh,et al. What causes the hippocampal volume decrease in depression? , 2007, European Archives of Psychiatry and Clinical Neuroscience.
[34] Anders M. Dale,et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.
[35] F. Holsboer,et al. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. , 2001, The American journal of pathology.
[36] A M Dale,et al. Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[37] Anders M. Dale,et al. Cortical Surface-Based Analysis I. Segmentation and Surface Reconstruction , 1999, NeuroImage.
[38] T. Brugha,et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. , 1990, Archives of general psychiatry.
[39] R. C. Young,et al. A Rating Scale for Mania: Reliability, Validity and Sensitivity , 1978, British Journal of Psychiatry.
[40] A. Beck,et al. An inventory for measuring depression. , 1961, Archives of general psychiatry.
[41] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[42] G. MacQueen,et al. Abnormal hippocampal activation in patients with extensive history of major depression: an fMRI study. , 2012, Journal of psychiatry & neuroscience : JPN.
[43] J. Aldenhoff,et al. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia , 2011, Molecular Psychiatry.
[44] G. MacQueen,et al. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. , 2009, Journal of psychiatry & neuroscience : JPN.
[45] T. Johnson,et al. Cognitive ^ behavioural therapy for severe and recurrent bipolar disorders Randomised controlled trial , 2006 .
[46] D. Kupfer,et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.
[47] Alan D. Lopez,et al. The Global Burden of Disease Study , 2003 .
[48] H. Sackeim,et al. The definition and meaning of treatment-resistant depression. , 2001, The Journal of clinical psychiatry.